BridgeBio Pharma Inc. (BBIO) Tops Q2 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BridgeBio Pharma (BBIO) PT Lowered to $45 at Citi
August 2, 2024 12:19 PM EDTCiti analyst David Lebowitz lowered the price target on BridgeBio Pharma (NASDAQ: BBIO) to $45.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "BridgeBio announced 2Q24 earnings, provided an update on its pipeline, and pointed toward key recent achievements. Mgt. also highlighted... More
